Stem cell therapy for heart failure: Ensuring regenerative proficiency

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.

Original languageEnglish (US)
Pages (from-to)395-404
Number of pages10
JournalTrends in cardiovascular medicine
Issue number5
StatePublished - Jul 1 2016


  • Cardiopoiesis
  • Cardiopoietic stem cell
  • Cardiovascular disease
  • Clinical trial
  • Clinomics
  • Epidemic
  • Health care
  • Myocardial infarction
  • Next generation
  • Quality
  • Regenerative medicine
  • System

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Stem cell therapy for heart failure: Ensuring regenerative proficiency'. Together they form a unique fingerprint.

Cite this